Literature DB >> 24191981

Ecological momentary assessment of posttraumatic stress disorder symptoms during a smoking quit attempt.

Eric A Dedert1, Paul A Dennis, Cindy M Swinkels, Patrick S Calhoun, Michelle F Dennis, Jean C Beckham.   

Abstract

INTRODUCTION: Smokers with posttraumatic stress disorder (PTSD) tend to lapse more quickly following a quit attempt, which might be explained by changes in PTSD symptoms during a quit attempt. The present study examines changes in PTSD symptoms, negative affect, and craving before and during a quit attempt.
METHODS: Participants in this study were 52 smokers with PTSD who completed random-alarm ecological momentary assessments of PTSD symptoms, negative affect, cigarette craving, and smoking behavior throughout a prequit phase of ad hoc smoking, a phase of abstinence from smoking, and a postlapse phase.
RESULTS: Relative to the prequit phase, the abstinent phase was marked by decreases in PTSD reexperiencing, avoidance, and numbing clusters (ps ≤ .01). The odds of PTSD symptom or negative affect variability from one reading in the ecological momentary assessment (EMA)to the next reading was decreased in PTSD reexperiencing, avoidance, and numbing clusters (ps ≤ .02). Smoking cravings were also mildly decreased in the abstinent and postlapse phases (ps < .01), although some cravings in both phases were rated at the maximum intensity. Increased craving was predicted by the previous EMA reading of PTSD symptoms.
CONCLUSIONS: Results suggested that smoking abstinence is not associated with exacerbation of PTSD symptoms, but PTSD symptoms during abstinence were related to craving levels during the quit attempt.

Entities:  

Mesh:

Year:  2013        PMID: 24191981      PMCID: PMC3954422          DOI: 10.1093/ntr/ntt167

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  27 in total

1.  Prevalence and correlates of heavy smoking in Vietnam veterans with chronic posttraumatic stress disorder.

Authors:  J C Beckham; A C Kirby; M E Feldman; M A Hertzberg; S D Moore; A L Crawford; J R Davidson; J A Fairbank
Journal:  Addict Behav       Date:  1997 Sep-Oct       Impact factor: 3.913

2.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Wai Tat Chiu; Olga Demler; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

3.  A day at a time: predicting smoking lapse from daily urge.

Authors:  S Shiffman; J B Engberg; J A Paty; W G Perz; M Gnys; J D Kassel; M Hickcox
Journal:  J Abnorm Psychol       Date:  1997-02

4.  Development and validation of brief measures of positive and negative affect: the PANAS scales.

Authors:  D Watson; L A Clark; A Tellegen
Journal:  J Pers Soc Psychol       Date:  1988-06

5.  Positive and negative affectivity and their relation to anxiety and depressive disorders.

Authors:  D Watson; L A Clark; G Carey
Journal:  J Abnorm Psychol       Date:  1988-08

Review 6.  The development of a Clinician-Administered PTSD Scale.

Authors:  D D Blake; F W Weathers; L M Nagy; D G Kaloupek; F D Gusman; D S Charney; T M Keane
Journal:  J Trauma Stress       Date:  1995-01

7.  Assessment of a new self-rating scale for post-traumatic stress disorder.

Authors:  J R Davidson; S W Book; J T Colket; L A Tupler; S Roth; D David; M Hertzberg; T Mellman; J C Beckham; R D Smith; R M Davison; R Katz; M E Feldman
Journal:  Psychol Med       Date:  1997-01       Impact factor: 7.723

Review 8.  Nesbitt's Paradox resolved? Stress and arousal modulation during cigarette smoking.

Authors:  A C Parrott
Journal:  Addiction       Date:  1998-01       Impact factor: 6.526

9.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.

Authors:  T F Heatherton; L T Kozlowski; R C Frecker; K O Fagerström
Journal:  Br J Addict       Date:  1991-09

10.  Symptoms of tobacco withdrawal. A replication and extension.

Authors:  J R Hughes; S W Gust; K Skoog; R M Keenan; J W Fenwick
Journal:  Arch Gen Psychiatry       Date:  1991-01
View more
  8 in total

1.  Posttraumatic stress disorder, smoking, and cortisol in a community sample of pregnant women.

Authors:  William D Lopez; Julia S Seng
Journal:  Addict Behav       Date:  2014-05-12       Impact factor: 3.913

2.  Predicted Impact of Nicotine Reduction on Smokers with Affective Disorders.

Authors:  Diann E Gaalema; Mollie E Miller; Jennifer W Tidey
Journal:  Tob Regul Sci       Date:  2015-07

3.  Pilot Cases of Combined Cognitive Processing Therapy and Smoking Cessation for Smokers With Posttraumatic Stress Disorder.

Authors:  Eric A Dedert; Patricia A Resick; Miles E McFall; Paul A Dennis; Maren Olsen; Jean C Beckham
Journal:  Behav Ther       Date:  2015-09-25

4.  Supplemental nicotine preloading for smoking cessation in posttraumatic stress disorder: Results from a randomized controlled trial.

Authors:  Paul A Dennis; Nathan A Kimbrel; Eric A Dedert; Jean C Beckham; Michelle F Dennis; Patrick S Calhoun
Journal:  Addict Behav       Date:  2016-03-11       Impact factor: 3.913

Review 5.  Cognitive Dysfunction, Affective States, and Vulnerability to Nicotine Addiction: A Multifactorial Perspective.

Authors:  Morgane Besson; Benoît Forget
Journal:  Front Psychiatry       Date:  2016-09-21       Impact factor: 4.157

Review 6.  Smoking cessation and reduction in people with chronic mental illness.

Authors:  Jennifer W Tidey; Mollie E Miller
Journal:  BMJ       Date:  2015-09-21

7.  The Impact of Co-occurring Post-traumatic Stress Disorder and Substance Use Disorders on Craving: A Systematic Review of the Literature.

Authors:  Fabien Renaud; Louise Jakubiec; Joel Swendsen; Melina Fatseas
Journal:  Front Psychiatry       Date:  2021-12-14       Impact factor: 4.157

8.  Pilot Trial of a Combined Cognitive Processing Therapy and Smoking Cessation Treatment.

Authors:  Eric A Dedert; Patricia A Resick; Paul A Dennis; Sarah M Wilson; Scott D Moore; Jean C Beckham
Journal:  J Addict Med       Date:  2019 Jul/Aug       Impact factor: 4.647

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.